HUTCHMED (LSE:HCM) has dosed the first patient in the Phase Ia dose-escalation part of a global first-in-human trial of HMPL-A830, its KRAS-EGFR antibody-targeted therapy conjugate. The first dose was given in China on 24 September 2026. Earlier in September the company agreed to license the candidate's rights outside Greater China to GSK.

What was announced

On 28 September 2026 HUTCHMED (China) Limited (LSE:HCM) announced that it has started a global clinical trial of HMPL-A830 in patients with solid tumours. The first patient was dosed in China on 24 September 2026.

The study is a first-in-human, multicentre, open-label trial in patients with unresectable, advanced or metastatic solid tumours, registered as NCT07718581. The current stage is a Phase Ia dose-escalation part, which aims to find the maximum tolerated dose and the optimal dose for expansion. A dose expansion part will follow. The trial is assessing safety, tolerability, pharmacokinetics, immunogenicity and preliminary efficacy. The announcement does not give a target patient number, a list of trial countries or a timetable for data.

The drug

HUTCHMED describes HMPL-A830 as an antibody-targeted therapy conjugate (ATTC). The company calls it a "first-in-class KRAS-payload leveraging synchronized EGFR inhibition." It links a highly selective and potent inhibitor of Kirsten rat sarcoma (KRAS), used as the payload, to an antibody against the epidermal growth Factor receptor (EGFR). The aim is to carry the KRAS inhibitor directly to tumours that express EGFR while blocking both signalling pathways together.

The company said its ATTCs "represent a next-generation approach to precision oncology, combining monoclonal antibodies with proprietary small-molecule inhibitor payload platforms to deliver dual mechanisms of action."

To explain the rationale, HUTCHMED cited KRAS mutation rates of about 44% in colorectal cancer, 34% in lung adenocarcinoma and up to 89% in pancreatic ductal adenocarcinoma.

The GSK agreement

On 3 September 2026 HUTCHMED agreed to grant a GSK Subsidiary exclusive worldwide rights to develop and commercialise HMPL-A830 outside mainland China, Hong Kong, Macau and Taiwan. HUTCHMED keeps the rights in those territories. Under the agreement HUTCHMED runs the global Phase I study, and GSK takes on later development and commercialisation. The deal is subject to customary closing conditions, including completion of any antitrust regulatory reviews, so it had not closed as of the 28 September announcement.

HUTCHMED's release of 3 September set out the financial terms. They comprise an upfront payment of US$110m, payable at closing, and up to US$1.185bn in development, regulatory and commercial milestone payments, for a total potential value of up to US$1.295bn. HUTCHMED would also receive tiered royalties on net sales, at rates that were not disclosed. GSK also received a right of first negotiation on one earlier-stage ATTC candidate. At the time, acting chief executive and chief financial officer Johnny Cheng said the collaboration was a "significant step" in maximising the drug's potential. Dr Hesham Abdullah, GSK's Senior Vice President and Global Head of Oncology R&D, said the "dual KRAS-EGFR mechanism of HMPL-A830 has the potential to significantly improve upon current standard of care." The milestone payments depend on future events and are not assured.

What to watch next

Phase I trials are designed mainly to establish safety and dosing rather than to confirm efficacy. HUTCHMED's forward-looking statements note uncertainty over the timing and outcome of clinical studies and over whether the data will be enough to support a new drug application in China, the US or elsewhere. The points to watch are closing of the GSK agreement and receipt of the upfront payment, progress through dose escalation, and any first safety or efficacy data. No date has been given for any of these.